NovaOnco JS Therapeutics

JS Therapeutics (also known as NovaOnco JS Therapeutics) is a clinical-stage biotechnology company specializing in the development of first-in-class small molecule therapeutics for cancer. The company leverages its proprietary platform to target the Ubiquitin-Proteasome System (UPS), specifically focusing on deubiquitinating enzymes (DUBs). Its lead program, JST-057, is a potent and selective USP7 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors and hematologic malignancies. JS Therapeutics maintains operations in both the United States and China, aiming to address significant unmet needs in oncology through innovative protein degradation and stabilization strategies.